Your shopping cart is currently empty

CM-272 is a dual G9a/DNA methyltransferases (DNMTs) inhibitor.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $67 | In Stock | In Stock | |
| 5 mg | $163 | In Stock | In Stock | |
| 10 mg | $289 | In Stock | In Stock | |
| 25 mg | $538 | In Stock | In Stock | |
| 50 mg | $753 | In Stock | In Stock | |
| 100 mg | $1,050 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $173 | In Stock | In Stock |
| Description | CM-272 is a dual G9a/DNA methyltransferases (DNMTs) inhibitor. |
| Targets&IC50 | DNMT1:382 nM, G9a:8 nM, DNMT3B:1200 nM (IC50), DNMT3A:85 nM, GLP:2 nM |
| In vitro | CM-272, inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death. CM-272 significantly prolongs survival of AML, ALL and DLBCL xenogeneic models. |
| In vivo | CM-272 (2.5 mg/kg; intravenous injection; daily; for 28 days; female Rag2?/?γc?/? mice) treatment significantly prolongs survival of CEMO-1 cells xenogeneic models.Induced a statistically significant increase in overall survival (OS) in mice. |
| Cell Research | Cell Line:CEMO-1, MV4-11 and OCI-Ly10 cell lines. Concentration:125 nM, 250 nM, 500 nM (CEMO-1 cells); 135 nM, 270 nM, 540 nM (MV4-11 cells); 100 nM, 400 nM, 1000 nM (OCI-Ly10 cells). Incubation Time:12 hours, 24 hours, 48 hours and 72?hours |
| Animal Research | CM-272 (2.5 mg/kg; intravenous injection; daily; for 28 days; female Rag2?/?γc?/? mice) treatment significantly prolongs survival of CEMO-1 cells xenogeneic models. Animal Model:Female BALB/Ca-Rag2?/?γc?/? mice (6–8-week-old) with CEMO-1 cells. Dosage:2.5 mg/kg. Administration:Intravenous injection; daily; for 28 days |
| Molecular Weight | 478.63 |
| Formula | C28H38N4O3 |
| Cas No. | 1846570-31-7 |
| Smiles | COc1cc2c(NC3CCN(C)CC3)cc(nc2cc1OCCCN1CCCC1)-c1ccc(C)o1 |
| Relative Density. | 1.164 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (522.32 mM), Sonication is recommended. Ethanol: 96 mg/mL (200.57 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.89 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.